Cariprazine and Mobocertinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mobocertinib
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's the situation. Cariprazine (Vraylar) is broken down by a liver enzyme called CYP3A4, and that same enzyme also creates cariprazine's active forms that do the real work. Mobocertinib (Exkivity) can speed up this enzyme. Because both the buildup and breakdown of cariprazine depend on this enzyme, no one can say for sure whether your cariprazine will end up too strong or too weak when the two are combined.
The good news is that this is a theoretical concern, and your care team can manage it. Please don't stop or change either medicine on your own. Let your pharmacist or doctor know you take both so they can watch how you're doing and adjust if needed.
Mechanism: Mobocertinib is a CYP3A4 inducer; cariprazine is a CYP3A4 substrate whose active metabolites (DDCAR) are both formed and eliminated via CYP3A4.
- Direction/magnitude: Net effect on cariprazine exposure is unpredictable because CYP3A4 governs both activation and clearance. Not formally evaluated.
- Onset: Unspecified (enzyme induction is typically delayed, days to weeks).
- Evidence: Theoretical.
- Management: Combination is not recommended per labeling. If used, monitor closely for loss of efficacy or emergent adverse effects and individualize dosing with the prescriber.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
Using cariprazine (which is metabolized by CYP3A4) together with a CYP3A4 inducer is advised against. The generation and clearance of cariprazine's active metabolites depend on CYP3A4. How CYP3A4 inducers alter cariprazine exposure has not been studied, so the overall outcome remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Decide whether this combination is appropriate, since the labeling says it is generally not recommended.
- Monitor you more closely, watching both for the return of symptoms and for new side effects, since the net effect on cariprazine is uncertain.
- Adjust and individualize your dose if needed.
What you should do: Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Tell your pharmacist and doctor that you take both, and report any changes in how you feel so they can respond.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cariprazine and Mobocertinib together?
Combining mobocertinib with cariprazine can unpredictably change cariprazine's effect and is generally not recommended, so ask your prescriber or pharmacist before using both and expect closer monitoring if you do. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Mobocertinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Mobocertinib interaction managed?
What your care team may do: Decide whether this combination is appropriate, since the labeling says it is generally not recommended. Monitor you more closely, watching both for the return of symptoms and for new side effects, since the net effect on cariprazine is uncertain. Adjust and individualize your dose if needed. What you should do: Keep taking both medicines exactly as prescribed unless yo… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cariprazine or Mobocertinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Mobocertinib
Keep reading about Cariprazine
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist